ID   NDST1_HUMAN             Reviewed;         882 AA.
AC   P52848; Q96E57;
DT   01-OCT-1996, integrated into UniProtKB/Swiss-Prot.
DT   01-OCT-1996, sequence version 1.
DT   10-MAY-2017, entry version 159.
DE   RecName: Full=Bifunctional heparan sulfate N-deacetylase/N-sulfotransferase 1;
DE            EC=2.8.2.8;
DE   AltName: Full=Glucosaminyl N-deacetylase/N-sulfotransferase 1;
DE            Short=NDST-1;
DE   AltName: Full=N-heparan sulfate sulfotransferase 1;
DE            Short=N-HSST 1;
DE   AltName: Full=[Heparan sulfate]-glucosamine N-sulfotransferase 1;
DE            Short=HSNST 1;
DE   Includes:
DE     RecName: Full=Heparan sulfate N-deacetylase 1;
DE              EC=3.-.-.-;
DE   Includes:
DE     RecName: Full=Heparan sulfate N-sulfotransferase 1;
DE              EC=2.8.2.-;
GN   Name=NDST1; Synonyms=HSST, HSST1;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1).
RC   TISSUE=Placenta;
RX   PubMed=7601448; DOI=10.1016/0888-7543(95)80206-2;
RA   Dixon J., Loftus S.K., Gladwin A.J., Scambler P.J., Wasmuth J.J.,
RA   Dixon M.J.;
RT   "Cloning of the human heparan sulfate-N-deacetylase/N-sulfotransferase
RT   gene from the Treacher Collins syndrome candidate region at 5q32-
RT   q33.1.";
RL   Genomics 26:239-244(1995).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), AND SUBCELLULAR LOCATION.
RC   TISSUE=Umbilical vein endothelial cell;
RX   PubMed=9230113; DOI=10.1042/bj3250351;
RA   Humphries D.E., Sullivan B.M., Aleixo M.D., Stow J.L.;
RT   "Localization of human heparan glucosaminyl N-deacetylase/N-
RT   sulphotransferase to the trans-Golgi network.";
RL   Biochem. J. 325:351-357(1997).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1).
RC   TISSUE=Fibroblast;
RA   Labell T.L., Milewicz D.J., Bonadio J., Edelhoff S., Disteche C.M.,
RA   Byers P.H.;
RL   Submitted (JUN-1995) to the EMBL/GenBank/DDBJ databases.
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 2).
RC   TISSUE=Lung;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [5]
RP   MUTAGENESIS OF LYS-614.
RX   PubMed=9744796; DOI=10.1016/S0014-5793(98)00913-2;
RA   Sueyoshi T., Kakuta Y., Pedersen L.C., Wall F.E., Pedersen L.G.,
RA   Negishi M.;
RT   "A role of Lys614 in the sulfotransferase activity of human heparan
RT   sulfate N-deacetylase/N-sulfotransferase.";
RL   FEBS Lett. 433:211-214(1998).
RN   [6]
RP   FUNCTION.
RX   PubMed=10758005; DOI=10.1021/bi992524l;
RA   Pikas D.S., Eriksson I., Kjellen L.;
RT   "Overexpression of different isoforms of glucosaminyl N-deacetylase/N-
RT   sulfotransferase results in distinct heparan sulfate N-sulfation
RT   patterns.";
RL   Biochemistry 39:4552-4558(2000).
RN   [7]
RP   FUNCTION, AND BIOPHYSICOCHEMICAL PROPERTIES.
RX   PubMed=12634318; DOI=10.1093/glycob/cwg011;
RA   van den Born J., Pikas D.S., Pisa B.J., Eriksson I., Kjellen L.,
RA   Berden J.H.M.;
RT   "Antibody-based assay for N-deacetylase activity of heparan
RT   sulfate/heparin N-deacetylase/N-sulfotransferase (NDST): novel
RT   characteristics of NDST-1 and -2.";
RL   Glycobiology 13:1-10(2003).
RN   [8]
RP   FUNCTION.
RX   PubMed=22660413; DOI=10.1038/ncb2502;
RA   Baietti M.F., Zhang Z., Mortier E., Melchior A., Degeest G.,
RA   Geeraerts A., Ivarsson Y., Depoortere F., Coomans C., Vermeiren E.,
RA   Zimmermann P., David G.;
RT   "Syndecan-syntenin-ALIX regulates the biogenesis of exosomes.";
RL   Nat. Cell Biol. 14:677-685(2012).
RN   [9]
RP   INTERACTION WITH EXT2.
RX   PubMed=18337501; DOI=10.1073/pnas.0705807105;
RA   Presto J., Thuveson M., Carlsson P., Busse M., Wilen M., Eriksson I.,
RA   Kusche-Gullberg M., Kjellen L.;
RT   "Heparan sulfate biosynthesis enzymes EXT1 and EXT2 affect NDST1
RT   expression and heparan sulfate sulfation.";
RL   Proc. Natl. Acad. Sci. U.S.A. 105:4751-4756(2008).
RN   [10]
RP   X-RAY CRYSTALLOGRAPHY (2.3 ANGSTROMS) OF 579-882 IN COMPLEX WITH PAP,
RP   AND DISULFIDE BOND.
RX   PubMed=10196134; DOI=10.1074/jbc.274.16.10673;
RA   Kakuta Y., Sueyoshi T., Negishi M., Pedersen L.C.;
RT   "Crystal structure of the sulfotransferase domain of human heparan
RT   sulfate N-deacetylase/N-sulfotransferase 1.";
RL   J. Biol. Chem. 274:10673-10676(1999).
RN   [11]
RP   INVOLVEMENT IN MRT46, AND VARIANTS MRT46 SER-611; LEU-640; ASP-642 AND
RP   GLN-709.
RX   PubMed=25125150; DOI=10.1002/ajmg.a.36723;
RA   Reuter M.S., Musante L., Hu H., Diederich S., Sticht H., Ekici A.B.,
RA   Uebe S., Wienker T.F., Bartsch O., Zechner U., Oppitz C., Keleman K.,
RA   Jamra R.A., Najmabadi H., Schweiger S., Reis A., Kahrizi K.;
RT   "NDST1 missense mutations in autosomal recessive intellectual
RT   disability.";
RL   Am. J. Med. Genet. A 164A:2753-2763(2014).
CC   -!- FUNCTION: Essential bifunctional enzyme that catalyzes both the N-
CC       deacetylation and the N-sulfation of glucosamine (GlcNAc) of the
CC       glycosaminoglycan in heparan sulfate. Modifies the GlcNAc-GlcA
CC       disaccharide repeating sugar backbone to make N-sulfated
CC       heparosan, a prerequisite substrate for later modifications in
CC       heparin biosynthesis (PubMed:10758005, PubMed:12634318). Plays a
CC       role in determining the extent and pattern of sulfation of heparan
CC       sulfate. Compared to other NDST enzymes, its presence is
CC       absolutely required. Participates in biosynthesis of heparan
CC       sulfate that can ultimately serve as L-selectin ligands, thereby
CC       playing a role in inflammatory response (PubMed:10758005,
CC       PubMed:12634318). Required for the exosomal release of SDCBP, CD63
CC       and syndecan (PubMed:22660413). {ECO:0000269|PubMed:10758005,
CC       ECO:0000269|PubMed:12634318, ECO:0000269|PubMed:22660413}.
CC   -!- CATALYTIC ACTIVITY: 3'-phosphoadenylyl sulfate + [heparan
CC       sulfate]-glucosamine = adenosine 3',5'-bisphosphate + [heparan
CC       sulfate]-N-sulfoglucosamine.
CC   -!- BIOPHYSICOCHEMICAL PROPERTIES:
CC       Kinetic parameters:
CC         KM=13.3 uM for K5 polysaccharide {ECO:0000269|PubMed:12634318};
CC         KM=0.35 uM for N-acetylated HS-II {ECO:0000269|PubMed:12634318};
CC   -!- PATHWAY: Glycan metabolism; heparan sulfate biosynthesis.
CC   -!- PATHWAY: Glycan metabolism; heparin biosynthesis.
CC   -!- SUBUNIT: Monomer (PubMed:10196134). Interacts with EXT2
CC       (PubMed:18337501). {ECO:0000269|PubMed:10196134,
CC       ECO:0000269|PubMed:18337501}.
CC   -!- SUBCELLULAR LOCATION: Golgi apparatus membrane
CC       {ECO:0000269|PubMed:9230113}; Single-pass type II membrane protein
CC       {ECO:0000269|PubMed:9230113}.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=2;
CC       Name=1;
CC         IsoId=P52848-1; Sequence=Displayed;
CC       Name=2;
CC         IsoId=P52848-2; Sequence=VSP_017397, VSP_017398;
CC         Note=No experimental confirmation available.;
CC   -!- TISSUE SPECIFICITY: Widely expressed. Expression is most abundant
CC       in heart, liver and pancreas.
CC   -!- DISEASE: Mental retardation, autosomal recessive 46 (MRT46)
CC       [MIM:616116]: A disorder characterized by significantly below
CC       average general intellectual functioning associated with
CC       impairments in adaptive behavior and manifested during the
CC       developmental period. MRT46 manifestations include delayed
CC       psychomotor development apparent from infancy or early childhood,
CC       delayed or absent expressive speech, hypotonia, and therapy-
CC       responsive seizures in some patients. Behavioral abnormalities are
CC       variable and include aggression, self-injurious behavior, and
CC       sleep disturbances. {ECO:0000269|PubMed:25125150}. Note=The
CC       disease is caused by mutations affecting the gene represented in
CC       this entry.
CC   -!- MISCELLANEOUS: The presence of 4 different heparan sulfate N-
CC       deacetylase/N-sulfotransferase enzymes in mammals, as well as
CC       differences in their enzyme activity suggest that some initiate
CC       heparan sulfate modification/sulfation reactions, whereas other
CC       later on fill in or extend already modified heparan sulfate
CC       sequences.
CC   -!- SIMILARITY: Belongs to the sulfotransferase 1 family. NDST
CC       subfamily. {ECO:0000305}.
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; U18918; AAA75281.1; -; mRNA.
DR   EMBL; U36600; AAC27354.1; -; mRNA.
DR   EMBL; U17970; AAA67765.1; -; mRNA.
DR   EMBL; BC012888; AAH12888.1; -; mRNA.
DR   CCDS; CCDS34277.1; -. [P52848-1]
DR   PIR; A57169; A57169.
DR   RefSeq; NP_001287992.1; NM_001301063.1.
DR   RefSeq; NP_001534.1; NM_001543.4. [P52848-1]
DR   RefSeq; XP_006714846.1; XM_006714783.1. [P52848-1]
DR   RefSeq; XP_016864917.1; XM_017009428.1. [P52848-1]
DR   RefSeq; XP_016864918.1; XM_017009429.1. [P52848-1]
DR   RefSeq; XP_016864919.1; XM_017009430.1. [P52848-1]
DR   RefSeq; XP_016864920.1; XM_017009431.1. [P52848-1]
DR   UniGene; Hs.222055; -.
DR   PDB; 1NST; X-ray; 2.30 A; A=558-882.
DR   PDBsum; 1NST; -.
DR   ProteinModelPortal; P52848; -.
DR   SMR; P52848; -.
DR   BioGrid; 109572; 12.
DR   STRING; 9606.ENSP00000261797; -.
DR   DrugBank; DB01812; Adenosine-3'-5'-Diphosphate.
DR   iPTMnet; P52848; -.
DR   PhosphoSitePlus; P52848; -.
DR   BioMuta; NDST1; -.
DR   EPD; P52848; -.
DR   MaxQB; P52848; -.
DR   PaxDb; P52848; -.
DR   PeptideAtlas; P52848; -.
DR   PRIDE; P52848; -.
DR   Ensembl; ENST00000261797; ENSP00000261797; ENSG00000070614. [P52848-1]
DR   GeneID; 3340; -.
DR   KEGG; hsa:3340; -.
DR   UCSC; uc003lsk.4; human. [P52848-1]
DR   CTD; 3340; -.
DR   DisGeNET; 3340; -.
DR   GeneCards; NDST1; -.
DR   HGNC; HGNC:7680; NDST1.
DR   HPA; HPA060532; -.
DR   MalaCards; NDST1; -.
DR   MIM; 600853; gene.
DR   MIM; 616116; phenotype.
DR   neXtProt; NX_P52848; -.
DR   OpenTargets; ENSG00000070614; -.
DR   Orphanet; 88616; Autosomal recessive non-syndromic intellectual disability.
DR   PharmGKB; PA31486; -.
DR   eggNOG; KOG3703; Eukaryota.
DR   eggNOG; ENOG410XQN4; LUCA.
DR   GeneTree; ENSGT00760000119023; -.
DR   HOGENOM; HOG000008010; -.
DR   HOVERGEN; HBG082011; -.
DR   InParanoid; P52848; -.
DR   KO; K02576; -.
DR   OMA; TNTIDYH; -.
DR   OrthoDB; EOG091G02CP; -.
DR   PhylomeDB; P52848; -.
DR   TreeFam; TF313193; -.
DR   BioCyc; MetaCyc:HS01001-MONOMER; -.
DR   Reactome; R-HSA-2022928; HS-GAG biosynthesis.
DR   SABIO-RK; P52848; -.
DR   UniPathway; UPA00756; -.
DR   UniPathway; UPA00862; -.
DR   ChiTaRS; NDST1; human.
DR   EvolutionaryTrace; P52848; -.
DR   GeneWiki; NDST1; -.
DR   GenomeRNAi; 3340; -.
DR   PRO; PR:P52848; -.
DR   Proteomes; UP000005640; Chromosome 5.
DR   Bgee; ENSG00000070614; -.
DR   CleanEx; HS_NDST1; -.
DR   ExpressionAtlas; P52848; baseline and differential.
DR   Genevisible; P52848; HS.
DR   GO; GO:0000139; C:Golgi membrane; TAS:Reactome.
DR   GO; GO:0016021; C:integral component of membrane; IEA:UniProtKB-KW.
DR   GO; GO:0015016; F:[heparan sulfate]-glucosamine N-sulfotransferase activity; TAS:Reactome.
DR   GO; GO:0050119; F:N-acetylglucosamine deacetylase activity; TAS:Reactome.
DR   GO; GO:0035904; P:aorta development; IEA:Ensembl.
DR   GO; GO:0003279; P:cardiac septum development; IEA:Ensembl.
DR   GO; GO:0060976; P:coronary vasculature development; IEA:Ensembl.
DR   GO; GO:0048702; P:embryonic neurocranium morphogenesis; IEA:Ensembl.
DR   GO; GO:0048703; P:embryonic viscerocranium morphogenesis; IEA:Ensembl.
DR   GO; GO:0008543; P:fibroblast growth factor receptor signaling pathway; IEA:Ensembl.
DR   GO; GO:0030900; P:forebrain development; IEA:Ensembl.
DR   GO; GO:0006024; P:glycosaminoglycan biosynthetic process; TAS:Reactome.
DR   GO; GO:0015012; P:heparan sulfate proteoglycan biosynthetic process; TAS:ProtInc.
DR   GO; GO:0030210; P:heparin biosynthetic process; IEA:UniProtKB-UniPathway.
DR   GO; GO:0006954; P:inflammatory response; IEA:UniProtKB-KW.
DR   GO; GO:0000165; P:MAPK cascade; IEA:Ensembl.
DR   GO; GO:0030901; P:midbrain development; IEA:Ensembl.
DR   GO; GO:0000271; P:polysaccharide biosynthetic process; IEA:Ensembl.
DR   GO; GO:0006477; P:protein sulfation; IEA:Ensembl.
DR   GO; GO:0007585; P:respiratory gaseous exchange; IEA:Ensembl.
DR   GO; GO:0007224; P:smoothened signaling pathway; IEA:Ensembl.
DR   InterPro; IPR021930; Heparan_SO4_deacetylase.
DR   InterPro; IPR027417; P-loop_NTPase.
DR   InterPro; IPR000863; Sulfotransferase_dom.
DR   Pfam; PF12062; HSNSD; 1.
DR   Pfam; PF00685; Sulfotransfer_1; 1.
DR   SUPFAM; SSF52540; SSF52540; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Alternative splicing; Complete proteome;
KW   Disease mutation; Disulfide bond; Glycoprotein; Golgi apparatus;
KW   Hydrolase; Inflammatory response; Membrane; Mental retardation;
KW   Multifunctional enzyme; Reference proteome; Signal-anchor;
KW   Transferase; Transmembrane; Transmembrane helix.
FT   CHAIN         1    882       Bifunctional heparan sulfate N-
FT                                deacetylase/N-sulfotransferase 1.
FT                                /FTId=PRO_0000085210.
FT   TOPO_DOM      1     17       Cytoplasmic. {ECO:0000255}.
FT   TRANSMEM     18     39       Helical; Signal-anchor for type II
FT                                membrane protein. {ECO:0000255}.
FT   TOPO_DOM     40    882       Lumenal. {ECO:0000255}.
FT   NP_BIND     614    618       PAPS. {ECO:0000269|PubMed:10196134}.
FT   NP_BIND     833    837       PAPS. {ECO:0000269|PubMed:10196134}.
FT   REGION       40    598       Heparan sulfate N-deacetylase 1.
FT   REGION      599    882       Heparan sulfate N-sulfotransferase 1.
FT   ACT_SITE    614    614       For sulfotransferase activity.
FT   BINDING     712    712       PAPS. {ECO:0000269|PubMed:10196134}.
FT   CARBOHYD    231    231       N-linked (GlcNAc...) asparagine.
FT                                {ECO:0000255}.
FT   CARBOHYD    351    351       N-linked (GlcNAc...) asparagine.
FT                                {ECO:0000255}.
FT   CARBOHYD    401    401       N-linked (GlcNAc...) asparagine.
FT                                {ECO:0000255}.
FT   CARBOHYD    667    667       N-linked (GlcNAc...) asparagine.
FT                                {ECO:0000255}.
FT   DISULFID    818    828       {ECO:0000269|PubMed:10196134}.
FT   VAR_SEQ     523    556       ISIFMTHLSNYGNDRLGLYTFKHLVRFLHSWTNL -> VSA
FT                                PQPMAAGEKGLLHSLSAADTGFLEPGKGGEA (in
FT                                isoform 2).
FT                                {ECO:0000303|PubMed:15489334}.
FT                                /FTId=VSP_017397.
FT   VAR_SEQ     557    882       Missing (in isoform 2).
FT                                {ECO:0000303|PubMed:15489334}.
FT                                /FTId=VSP_017398.
FT   VARIANT     611    611       G -> S (in MRT46; dbSNP:rs606231459).
FT                                {ECO:0000269|PubMed:25125150}.
FT                                /FTId=VAR_072646.
FT   VARIANT     640    640       F -> L (in MRT46; dbSNP:rs606231458).
FT                                {ECO:0000269|PubMed:25125150}.
FT                                /FTId=VAR_072647.
FT   VARIANT     642    642       E -> D (in MRT46; dbSNP:rs606231457).
FT                                {ECO:0000269|PubMed:25125150}.
FT                                /FTId=VAR_072648.
FT   VARIANT     709    709       R -> Q (in MRT46; dbSNP:rs606231456).
FT                                {ECO:0000269|PubMed:25125150}.
FT                                /FTId=VAR_072649.
FT   MUTAGEN     614    614       K->A: Loss of sulfotransferase activity.
FT                                {ECO:0000269|PubMed:9744796}.
FT   CONFLICT     24     28       FIFCL -> QVVCQ (in Ref. 4; AAH12888).
FT                                {ECO:0000305}.
FT   CONFLICT     60     60       P -> A (in Ref. 3; AAA67765).
FT                                {ECO:0000305}.
FT   CONFLICT    364    364       H -> Q (in Ref. 4; AAH12888).
FT                                {ECO:0000305}.
FT   CONFLICT    689    689       R -> G (in Ref. 3; AAA67765).
FT                                {ECO:0000305}.
FT   CONFLICT    743    743       K -> R (in Ref. 3; AAA67765).
FT                                {ECO:0000305}.
FT   STRAND      604    609       {ECO:0000244|PDB:1NST}.
FT   HELIX       617    625       {ECO:0000244|PDB:1NST}.
FT   STRAND      630    632       {ECO:0000244|PDB:1NST}.
FT   TURN        637    639       {ECO:0000244|PDB:1NST}.
FT   STRAND      646    648       {ECO:0000244|PDB:1NST}.
FT   HELIX       649    653       {ECO:0000244|PDB:1NST}.
FT   HELIX       655    659       {ECO:0000244|PDB:1NST}.
FT   STRAND      672    676       {ECO:0000244|PDB:1NST}.
FT   HELIX       679    682       {ECO:0000244|PDB:1NST}.
FT   HELIX       686    693       {ECO:0000244|PDB:1NST}.
FT   STRAND      698    703       {ECO:0000244|PDB:1NST}.
FT   HELIX       706    719       {ECO:0000244|PDB:1NST}.
FT   HELIX       723    727       {ECO:0000244|PDB:1NST}.
FT   HELIX       730    734       {ECO:0000244|PDB:1NST}.
FT   HELIX       742    752       {ECO:0000244|PDB:1NST}.
FT   HELIX       753    755       {ECO:0000244|PDB:1NST}.
FT   HELIX       757    765       {ECO:0000244|PDB:1NST}.
FT   HELIX       770    772       {ECO:0000244|PDB:1NST}.
FT   STRAND      773    777       {ECO:0000244|PDB:1NST}.
FT   HELIX       778    783       {ECO:0000244|PDB:1NST}.
FT   HELIX       785    796       {ECO:0000244|PDB:1NST}.
FT   HELIX       805    807       {ECO:0000244|PDB:1NST}.
FT   STRAND      808    811       {ECO:0000244|PDB:1NST}.
FT   TURN        812    815       {ECO:0000244|PDB:1NST}.
FT   STRAND      816    820       {ECO:0000244|PDB:1NST}.
FT   HELIX       842    866       {ECO:0000244|PDB:1NST}.
FT   HELIX       872    878       {ECO:0000244|PDB:1NST}.
SQ   SEQUENCE   882 AA;  100868 MW;  D4B716B84A0BF4C4 CRC64;
     MPALACLRRL CRHVSPQAVL FLLFIFCLFS VFISAYYLYG WKRGLEPSAD APEPDCGDPP
     PVAPSRLLPL KPVQAATPSR TDPLVLVFVE SLYSQLGQEV VAILESSRFK YRTEIAPGKG
     DMPTLTDKGR GRFALIIYEN ILKYVNLDAW NRELLDKYCV AYGVGIIGFF KANENSLLSA
     QLKGFPLFLH SNLGLKDCSI NPKSPLLYVT RPSEVEKGVL PGEDWTVFQS NHSTYEPVLL
     AKTRSSESIP HLGADAGLHA ALHATVVQDL GLHDGIQRVL FGNNLNFWLH KLVFVDAVAF
     LTGKRLSLPL DRYILVDIDD IFVGKEGTRM KVEDVKALFD TQNELRAHIP NFTFNLGYSG
     KFFHTGTNAE DAGDDLLLSY VKEFWWFPHM WSHMQPHLFH NQSVLAEQMA LNKKFAVEHG
     IPTDMGYAVA PHHSGVYPVH VQLYEAWKQV WSIRVTSTEE YPHLKPARYR RGFIHNGIMV
     LPRQTCGLFT HTIFYNEYPG GSSELDKIIN GGELFLTVLL NPISIFMTHL SNYGNDRLGL
     YTFKHLVRFL HSWTNLRLQT LPPVQLAQKY FQIFSEEKDP LWQDPCEDKR HKDIWSKEKT
     CDRFPKLLII GPQKTGTTAL YLFLGMHPDL SSNYPSSETF EEIQFFNGHN YHKGIDWYME
     FFPIPSNTTS DFYFEKSANY FDSEVAPRRA AALLPKAKVL TILINPADRA YSWYQHQRAH
     DDPVALKYTF HEVITAGSDA SSKLRALQNR CLVPGWYATH IERWLSAYHA NQILVLDGKL
     LRTEPAKVMD MVQKFLGVTN TIDYHKTLAF DPKKGFWCQL LEGGKTKCLG KSKGRKYPEM
     DLDSRAFLKD YYRDHNIELS KLLYKMGQTL PTWLREDLQN TR
//
